Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin
Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin

Immune Cell CAR-T Therapy A Revolutionary Breakthrough in Modern Cancer Treatment

In recent years, Immune cell CAR-T therapy (Chimeric Antigen Receptor T-cell Therapy) has emerged as one of the most revolutionary directions in cancer treatment within modern medicine.

Immune Cell CAR-T Therapy
- A Revolutionary Breakthrough
in Modern Cancer Treatment

In recent years, Immune cell CAR-T therapy (Chimeric Antigen Receptor T-cell Therapy) has emerged as one of the most revolutionary directions in cancer treatment within modern medicine.

This approach has brought new hope to patients with hematological cancers, lymphomas, systemic lupus erythematosus, and acute leukemia who do not respond to traditional chemotherapy or radiotherapy.
By “training” a patient’ s own immune cells to recognize and kill cancer cells, CAR-T therapy is regarded as a major leap in personalized treatment. Its goal has shifted from “extending life” to “curing the disease”.

What is CAR-T?

CAR-T is a therapy that uses a patient’ s own T cells (key white blood cells in the immune system). These T cells are genetically engineered in a laboratory to express a special receptor – CAR (Chimeric Antigen Receptor), enabling them to accurately recognize and attack cancer cells.

Collect T cells

Collect T cells from the patient’ s blood

Genetic modification

Genetically modify the T cells to carry CAR receptors, which can r ecognize specific tumor antigens (such as CD19, BCMA, etc.)

In vitro expansion

Massively expand the modified CAR-T cells in the laboratory

Infuse back into the body

Infuse these "programmed" CAR T cells back into the patient’s body through an intravenous drip

Targeted elimination

After entering the body, the CART cells act like "intelligent guards" to accurately target and eliminate cancer cells carrying the target antigen.

CAR-T vs Chemotherapy vs Radiotherapy

Therapeutic Approach Mechanism of Action Selectivity for Cancer Cells Impact on Normal Cells Sustained Efficacy
Chemotherapy Kills rapidly dividing cells Low High Limited
Radiotherapy Damages DNA to kill cells in the irradiated area Moderate May affect surrounding tissues Moderate
CAR-T Immune cells accurately recognize and eliminate target antigens Extremely High Extremely Low Long-lasting immune memory

CAR-T cells possess a “memory” function, allowing them to monitor the body for a long time after treatment and prevent cancer recurrence.

Significant Efficacy of CAR-T in Hematological Tumors

CAR-T therapy has been approved by the U.S. FDA for the treatment of various hematological malignancies, including:
  • Acute Lymphoblastic Leukemia (ALL), especially in children and young patients
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Multiple Myeloma, with new-generation CAR-T products targeting the BCMA antigen

Expansion of CAR-T to Solid Tumors

Initially, CAR-T was mainly used for hematological tumors, as their cells are easily accessible to targets in the blood.
However, researchers are actively exploring its application in solid tumors, such as lung cancer, liver cancer, gastric cancer, and ovarian cancer.

Although challenges such as tumor immune barriers, complex tumor microenvironments, and antigen loss still exist, preliminary results indicate that CAR-T also has great potential in solid tumor treatment.

China-Leading CAR-T Therapy in the World

China is currently one of the fastest-growing countries in global CAR-T development, with over 1,200 registered clinical trials – surpassing the United States in quantity.

Some leading hospitals include:

Fudan University Shanghai Cancer Center (Shanghai):

Huashan Hospital Affiliated to Fudan University:

Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine:

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Some domestically developed CAR-T products

Relmacabtagene autoleucel-Relma-cel

have been approved for marketing by China’s National Medical Products Administration (NMPA) bringing new treatment opportunities to thousands of hematological cancer patients.

Future Outlook: Moving Toward Precision Personalized Treatment

Current research is focused on the following directions:

Next-generation CAR-T

Capable of recognizing multiple tumor antigens simultaneously

CAR-NK / CAR-macrophages

Expanding to other types of immune cells

"Off-the-shelf" CAR-T

Using T cells from healthy donors to significantly reduce costs and waiting time

Combination of CAR-T and immune checkpoint inhibitors (PD-1/PD-L1)

Enhancing anti-cancer efficacy.

CAR-T is expected to become a core pillar of personalized cancer treatment, bringing new vitality to
millions of patients worldwide.

CAR-T Treatment Costs

Due to its complex personalized process, CAR-T therapy is generally more expensive than traditional treatments. Globally, the cost per course ranges from approximately 55,000 to 200,000 US dollars, depending on the country and product type. Some new-generation CAR-T products or clinical trial programs may offer fee reductions or subsidies. The actual cost depends on the type of cancer, the number of infusions, hospital stay duration, and complications.
In China, some hospitals have launched comprehensive treatment packages, preferential plans, and patient assistance programs to significantly reduce the overall treatment burden. CAR-T cell immunotherapy is a revolutionary milestone in modern cancer treatment, especially for patients with refractory or relapsed cancer.
Despite high costs and strict technical requirements, driven by China and other leading medical centers, CAR-T is leading cancer treatment into a new era of “precision medicine and personalized immunotherapy”.

Find Out if You Are Eligible for CAR-T Immunotherapy

Make an appointment now for a free professional consultation with Chinese oncology experts!